Bayer's Legal and Operational Crossroads: A $7.25 Billion Gamble

Bayer's share price has nearly doubled, fueled by a key US Supreme Court glyphosate case and strong drug sales. Analysts see value with a 2026 P/E of 8.7.

The Bayer share price, trading at 41.52 EUR, has nearly doubled from its 52-week low of 20.80 EUR, reflecting a market betting on a corporate turnaround. This remarkable surge hinges on two parallel tracks: a decisive legal strategy to contain legacy liabilities and a burgeoning pharmaceutical pipeline finally delivering growth. The coming weeks will test both fronts simultaneously.

Central to the investment thesis is the escalating legal battle over glyphosate. On April 27, oral arguments begin before the US Supreme Court. Bayer’s core argument is that the federal FIFRA law preempts state-level warning requirements for its Roundup herbicide. A favorable ruling could invalidate the foundation for tens of thousands of future Non-Hodgkin lymphoma lawsuits nationwide. The Trump administration supports this position, while attorneys general from 18 states, including Texas and Florida, have filed briefs defending state sovereignty.

Alongside this judicial path, the company is securing a financial backstop. A Missouri judge granted preliminary approval to a proposed $7.25 billion settlement package on March 4. Claimants have until June 4 to opt out. This move is part of a staggering legal bill; since 2018, Bayer has spent over $11 billion on litigation. The financial drain is palpable, with the company forecasting negative free cash flow for 2026 due to roughly 5 billion EUR in expected payouts this year. Net financial debt, however, did decrease by 8.5% to just under 29.8 billion EUR.

Operationally, the pharmaceutical division is providing crucial ballast. The company confirms its 2026 guidance, targeting an adjusted EBITDA of 9.6 to 10.1 billion EUR. US import tariffs on pharmaceuticals, capped at 15% for European medicines under a trade agreement, have not forced a forecast revision. Growth is being driven by products like the kidney and heart drug Kerendia, which posted a currency-adjusted sales increase of 88% last year and successfully met the primary endpoint of its FIND-CKD study. Another key drug, Nubeqa, is also exceeding market expectations.

The broader corporate overhaul under CEO Bill Anderson has seen 12,000 positions cut, aiming for annual savings of $2.3 billion. The pipeline holds further promise with candidates like the anticoagulant Asundexian and the menopause treatment Lynkuet nearing launch. This operational momentum is catching analysts' eyes. UBS recently upgraded the stock to "Buy," raising its price target from 48 to 52 EUR, while DZ Bank moved to "Hold." Trading at a 2026 P/E of just 8.7—a 37% discount to the European pharma sector average of 14.1—the valuation remains compelling. Seven out of nine analysts currently rate the stock a Buy or Strong Buy.

The corporate calendar is now densely packed. The virtual Annual General Meeting on April 24 will see a vote on an unchanged dividend of 0.11 EUR per share. Shortly after, the Supreme Court hearing represents the true billion-dollar risk. A decision in Bayer’s favor by the end of the court's session in June could fundamentally alter the litigation landscape. The subsequent fairness hearing for the final settlement approval is scheduled for July 9.

For investors, the narrative is clear. The stock’s dramatic recovery prices in significant legal relief and sustained operational execution. The twin events of late April—the AGM and the Supreme Court arguments—will determine whether this confidence is justified or if the shadow of Monsanto will lengthen once more. The company’s future valuation swings on this legal pivot point.